AIM:To assess the prevalence of human papilloma virus(HPV) in esophageal squamous cell carcinoma(ESCC) in the south-eastern region of Poland.METHODS:The study population consisted of 56 ESCC patients and 35 controls.T...AIM:To assess the prevalence of human papilloma virus(HPV) in esophageal squamous cell carcinoma(ESCC) in the south-eastern region of Poland.METHODS:The study population consisted of 56 ESCC patients and 35 controls.The controls were patients referred to our department due to other nonesophageal and non-oncological disorders with no gross or microscopic esophageal pathology as confirmed by endoscopy and histopathology.In the ESCC patients,samples were taken from normal mucosa(56 mucosa samples) and from the tumor(56 tumor samples).Tissue samples from the controls were taken from normal mucosa of the middle esophagus(35 control samples).Quantitative determination of DNA was carried out using a spectrophotometric method.Genomic DNA was isolated using the QIAamp DNA Midi Kit.HPV infection was identified following PCR amplification of the HPV gene sequence,using primers MY09 and MY11 complementary to the genome sequence of at least 33 types of HPV.The sequencing results were computationally analyzed using the basic local alignment search tool database.RESULTS:In tumor samples,HPV DNA was identified in 28 of 56 patients(50%).High risk HPV phenotypes(16 or/and 18) were found in 5 of 56 patients(8.9%),low risk in 19 of 56 patients(33.9%) and other types of HPV(37,81,97,CP6108) in 4 of 56 patients(7.1%).In mucosa samples,HPV DNA was isolated in 21 of 56 patients(37.5%).High risk HPV DNA was confirmed in 3 of 56 patients(5.3%),low risk HPV DNA in 12 of 56 patients(21.4%),and other types of HPV in 6 of 56 patients(10.7%).In control samples,HPV DNA was identified in 4 of 35 patients(11.4%) with no high risk HPV.The occurrence of HPV in ESCC patients was significantly higher than in the controls [28 of 56(50%) vs 4 of 35(11.4%),P < 0.001].In esophageal cancer patients,both in tumor and mucosa samples,the predominant HPV phenotypes were low risk HPV,isolated 4 times more frequently than high risk phenotypes [19 of 56(33.9%) vs 5 of 56(8.9%),P < 0.001].A higher prevalence of HPV was identified in female patients(71.4% vs 46.9%展开更多
目的比较低温等离子射频消融术与CO2激光治疗早期声门型喉癌的临床疗效。方法选取2007年10月~2012年12月行手术治疗的104例早期声门型喉癌（Tis、T1a、T1b）患者,其中64例行低温等离子射频消融术（等离子组）,40例行CO2激光切除术（CO2...目的比较低温等离子射频消融术与CO2激光治疗早期声门型喉癌的临床疗效。方法选取2007年10月~2012年12月行手术治疗的104例早期声门型喉癌（Tis、T1a、T1b）患者,其中64例行低温等离子射频消融术（等离子组）,40例行CO2激光切除术（CO2激光组）。记录并比较两组手术时间、术后第二日疼痛程度[视觉模拟评分法（visual analog scale,VAS）]评分;所有患者于术后一周、1个月及3个月行电子喉镜及嗓音声学分析,并进行随访观察。结果等离子组平均手术时间为8.75±1.62min,CO2激光组平均手术时间为11.82±1.51min,等离子组优于CO2激光组（P〈0.05）。术后第二日VAS评分等离子组（2.79±0.47分）与CO2激光组（2.96±0.64分）组间差异无统计学意义（P〉0.05）。等离子组术后1个月粘膜恢复情况好于CO2激光组（χ2=13.842,P〈0.05）。单因素重复测量分析结果显示：等离子组及CO2激光组术后嗓音声学指标jitter、shimmer、HNR随术后时间延长逐渐好转,在术后3个时间点的变化差异有统计学意义（P〈0.05）,且呈线性变化趋势。多因素重复测量方差分析结果显示：嗓音声学指标（jitter、shimmer、HNR）在术后3个时间点两组间差异均有统计学意义（P〈0.05）。等离子组与CO2激光组术后3年生存率、局部复发率、侵及前联合复发率、前联合术后粘连率组间差异均无统计学意义（P〉0.05）。两组所有患者均未行气管切开术,术后无呛咳,无呼吸困难,无严重疼痛及咯血等严重并发症。结论低温等离子射频消融术与CO2激光治疗早期声门型喉癌均较安全、有效,而低温等离子射频消融术手术时间较CO2激光手术短,术后一月粘膜恢复及嗓音恢复均优于CO2激光手术。展开更多
AIM: To further characterize the possible relationship between the molecular changes and prognosis of ESC and to elucidate the possible mechanisms involved.METHODS: 114 specimens of ESC were collected from Linzhou cit...AIM: To further characterize the possible relationship between the molecular changes and prognosis of ESC and to elucidate the possible mechanisms involved.METHODS: 114 specimens of ESC were collected from Linzhou city, and all patients were followed up for more than 5 years after resection. Histopathological analysis and immunohistochemical staining (ABC) were employed to detect the alteration of MUC1.RESULTS: The positive immunostaining rate for MUC1 was 79 % (90/114), and the high-expression rate was 63 %(72/114). The mean survival periods (months) of those with high- and low-expression rates of MUC1 were 41 (95 % CI:35, 47) and 52 (95 % CI: 45, 59), respectively. Patients in the low-expression group obviously survived longer than those in high-expression group, and the difference was significant (P＜0.05). The expression of MUC1 protein in the esophageal carcinoma specimens with metastasis was stronger than those without metastasis, the difference was also significant (P＜0.05). The stepwise multivariate analysis showed that 'differentiation', 'expression of MUC1' and 'TNM staging' were the most important factors affecting the prognosis of esophageal carcinoma patients (P＜0.05).CONCLUSION: A good correlation between the alteration of MUC1 and the regional lymph node metastasis was observed. Furthermore, high-expression of MUC1 was associated with poor prognosis for esophageal cancer patients. These results indicated that MUC1 is a promising biomarker for predicting lymph node metastasis and prognosis in esophageal cancer.展开更多
基金Supported by Medical University of Lublin,Scientific Research Grant
文摘AIM:To assess the prevalence of human papilloma virus(HPV) in esophageal squamous cell carcinoma(ESCC) in the south-eastern region of Poland.METHODS:The study population consisted of 56 ESCC patients and 35 controls.The controls were patients referred to our department due to other nonesophageal and non-oncological disorders with no gross or microscopic esophageal pathology as confirmed by endoscopy and histopathology.In the ESCC patients,samples were taken from normal mucosa(56 mucosa samples) and from the tumor(56 tumor samples).Tissue samples from the controls were taken from normal mucosa of the middle esophagus(35 control samples).Quantitative determination of DNA was carried out using a spectrophotometric method.Genomic DNA was isolated using the QIAamp DNA Midi Kit.HPV infection was identified following PCR amplification of the HPV gene sequence,using primers MY09 and MY11 complementary to the genome sequence of at least 33 types of HPV.The sequencing results were computationally analyzed using the basic local alignment search tool database.RESULTS:In tumor samples,HPV DNA was identified in 28 of 56 patients(50%).High risk HPV phenotypes(16 or/and 18) were found in 5 of 56 patients(8.9%),low risk in 19 of 56 patients(33.9%) and other types of HPV(37,81,97,CP6108) in 4 of 56 patients(7.1%).In mucosa samples,HPV DNA was isolated in 21 of 56 patients(37.5%).High risk HPV DNA was confirmed in 3 of 56 patients(5.3%),low risk HPV DNA in 12 of 56 patients(21.4%),and other types of HPV in 6 of 56 patients(10.7%).In control samples,HPV DNA was identified in 4 of 35 patients(11.4%) with no high risk HPV.The occurrence of HPV in ESCC patients was significantly higher than in the controls [28 of 56(50%) vs 4 of 35(11.4%),P < 0.001].In esophageal cancer patients,both in tumor and mucosa samples,the predominant HPV phenotypes were low risk HPV,isolated 4 times more frequently than high risk phenotypes [19 of 56(33.9%) vs 5 of 56(8.9%),P < 0.001].A higher prevalence of HPV was identified in female patients(71.4% vs 46.9%
文摘目的比较低温等离子射频消融术与CO2激光治疗早期声门型喉癌的临床疗效。方法选取2007年10月~2012年12月行手术治疗的104例早期声门型喉癌（Tis、T1a、T1b）患者,其中64例行低温等离子射频消融术（等离子组）,40例行CO2激光切除术（CO2激光组）。记录并比较两组手术时间、术后第二日疼痛程度[视觉模拟评分法（visual analog scale,VAS）]评分;所有患者于术后一周、1个月及3个月行电子喉镜及嗓音声学分析,并进行随访观察。结果等离子组平均手术时间为8.75±1.62min,CO2激光组平均手术时间为11.82±1.51min,等离子组优于CO2激光组（P〈0.05）。术后第二日VAS评分等离子组（2.79±0.47分）与CO2激光组（2.96±0.64分）组间差异无统计学意义（P〉0.05）。等离子组术后1个月粘膜恢复情况好于CO2激光组（χ2=13.842,P〈0.05）。单因素重复测量分析结果显示：等离子组及CO2激光组术后嗓音声学指标jitter、shimmer、HNR随术后时间延长逐渐好转,在术后3个时间点的变化差异有统计学意义（P〈0.05）,且呈线性变化趋势。多因素重复测量方差分析结果显示：嗓音声学指标（jitter、shimmer、HNR）在术后3个时间点两组间差异均有统计学意义（P〈0.05）。等离子组与CO2激光组术后3年生存率、局部复发率、侵及前联合复发率、前联合术后粘连率组间差异均无统计学意义（P〉0.05）。两组所有患者均未行气管切开术,术后无呛咳,无呼吸困难,无严重疼痛及咯血等严重并发症。结论低温等离子射频消融术与CO2激光治疗早期声门型喉癌均较安全、有效,而低温等离子射频消融术手术时间较CO2激光手术短,术后一月粘膜恢复及嗓音恢复均优于CO2激光手术。
基金National Outstanding Young Scientist Award of China ,NO.30025016NCI CA65871(U.S.A.)
文摘AIM: To further characterize the possible relationship between the molecular changes and prognosis of ESC and to elucidate the possible mechanisms involved.METHODS: 114 specimens of ESC were collected from Linzhou city, and all patients were followed up for more than 5 years after resection. Histopathological analysis and immunohistochemical staining (ABC) were employed to detect the alteration of MUC1.RESULTS: The positive immunostaining rate for MUC1 was 79 % (90/114), and the high-expression rate was 63 %(72/114). The mean survival periods (months) of those with high- and low-expression rates of MUC1 were 41 (95 % CI:35, 47) and 52 (95 % CI: 45, 59), respectively. Patients in the low-expression group obviously survived longer than those in high-expression group, and the difference was significant (P＜0.05). The expression of MUC1 protein in the esophageal carcinoma specimens with metastasis was stronger than those without metastasis, the difference was also significant (P＜0.05). The stepwise multivariate analysis showed that 'differentiation', 'expression of MUC1' and 'TNM staging' were the most important factors affecting the prognosis of esophageal carcinoma patients (P＜0.05).CONCLUSION: A good correlation between the alteration of MUC1 and the regional lymph node metastasis was observed. Furthermore, high-expression of MUC1 was associated with poor prognosis for esophageal cancer patients. These results indicated that MUC1 is a promising biomarker for predicting lymph node metastasis and prognosis in esophageal cancer.
